Inhibitory FcγRIIb and CD20 internalization.
Blood
; 123(5): 606-7, 2014 Jan 30.
Article
en En
| MEDLINE
| ID: mdl-24482497
ABSTRACT
In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based therapeutics (see figure).
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Receptores de IgG
/
Anticuerpos Monoclonales
Límite:
Humans
Idioma:
En
Revista:
Blood
Año:
2014
Tipo del documento:
Article